NasdaqGM:CLXT

Stock Analysis Report

Executive Summary

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Calyxt has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Calyxt's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.6%

NasdaqGM:CLXT

3.3%

US Biotechs

2.9%

US Market


1 Year Return

-60.7%

NasdaqGM:CLXT

-8.8%

US Biotechs

0.2%

US Market

CLXT underperformed the Biotechs industry which returned -9.1% over the past year.

CLXT underperformed the Market in United States of America which returned -0.7% over the past year.


Share holder returns

CLXTIndustryMarket
7 Day8.6%3.3%2.9%
30 Day-26.9%2.4%-2.3%
90 Day-53.5%3.4%3.1%
1 Year-60.7%-60.7%-8.1%-8.8%2.4%0.2%
3 Yearn/a12.0%8.2%41.7%32.4%
5 Yearn/a5.8%0.9%55.1%37.9%

Price Volatility Vs. Market

How volatile is Calyxt's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Calyxt undervalued based on future cash flows and its price relative to the stock market?

2.79x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Calyxt to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Calyxt to establish if it is available at substantial discount.


Price Based on Earnings

Calyxt is loss making, we can't compare its value to the US Biotechs industry average.

Calyxt is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Calyxt, we can't assess if its growth is good value.


Price Based on Value of Assets

Calyxt is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Calyxt expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

27.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Calyxt's revenue is expected to grow significantly at over 20% yearly.

Calyxt is not considered high growth as it is expected to be loss making for the next 1-3 years.

Calyxt's revenue growth is expected to exceed the United States of America market average.

Unable to compare Calyxt's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Calyxt's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Calyxt will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Calyxt performed over the past 5 years?

-36.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Calyxt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Calyxt's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Calyxt's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Calyxt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Calyxt has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Calyxt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Calyxt's financial position?


Financial Position Analysis

Calyxt is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Calyxt's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Calyxt has no debt.

Calyxt currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

High level of physical assets or inventory.

Calyxt has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Calyxt has sufficient cash runway for 2.6 years based on current free cash flow.

Calyxt has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 30.3% each year.


Next Steps

Dividend

What is Calyxt's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Calyxt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Calyxt's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Calyxt has not reported any payouts.

Unable to verify if Calyxt's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Calyxt has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Calyxt's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Calyxt's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Jim Blome (56yo)

0.8yrs

Tenure

US$5,229,684

Compensation

Mr. James A. Blome, also known as Jim, is the Chief Executive Officer of Calyxt since October 1, 2018. He was President and Chief Executive Officer of Bayer CropScience LP till September 2018. He serves as ...


CEO Compensation Analysis

Jim's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Jim to compare compensation growth.


Management Age and Tenure

0.6yrs

Average Tenure

47.5yo

Average Age

The average tenure for the Calyxt management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.1yrs

Average Tenure

54yo

Average Age

The average tenure for the Calyxt board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$46,12927 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$17.87
SellUS$44,71321 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$17.32
SellUS$42,80215 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$16.58
SellUS$332,50415 Mar 19
Yves Ribeill
EntityIndividual
Role
Member of the Board of Directors
Director
Shares19,980
Max PriceUS$17.39

Ownership Breakdown


Management Team

  • Jim Blome (56yo)

    Chief Executive Officer

    • Tenure: 0.8yrs
    • Compensation: US$5.23m
  • Dan Voytas (56yo)

    Founder & Chief Science Officer

    • Tenure: 0.0yrs
    • Compensation: US$282.67k
  • Simon Harnest

    VP of Corporate Strategy & Finance

    • Tenure: 0.0yrs
  • Eric Dutang (45yo)

    Principal Accounting Officer

    • Tenure: 1.2yrs
  • Manoj Sahoo (44yo)

    Chief Commercial Officer

    • Tenure: 2.4yrs
    • Compensation: US$407.49k
  • Bill Koschak (50yo)

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Debra Frimerman (39yo)

    General Counsel

    • Tenure: 0.5yrs
  • Travis Frey

    Chief Technology Officer

    • Tenure: 0.3yrs
  • Trina Lundblad

    Director of Communications

    • Tenure: 0.2yrs

Board Members

  • Yves Ribeill (59yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$6.31m
  • Jonathan Fassberg (53yo)

    Director

    • Tenure: 1.0yrs
    • Compensation: US$534.36k
  • Chris Neugent (58yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$528.11k
  • Kim Nelson (51yo)

    Director

    • Tenure: 0.6yrs
  • André Choulika (54yo)

    Chairman of the Board

    • Tenure: 9.0yrs
    • Compensation: US$65.00k
  • Anna Kozicz-Stankiewicz (44yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$50.00k
  • Philippe Dumont (68yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$65.00k

Company Information

Calyxt, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calyxt, Inc.
  • Ticker: CLXT
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$223.489m
  • Shares outstanding: 32.87m
  • Website: https://www.calyxt.com

Number of Employees


Location

  • Calyxt, Inc.
  • 2800 Mount Ridge Road
  • Roseville
  • Minnesota
  • 55113
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLXTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2017

Biography

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 00:53
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.